Boehringer Accused Of Monopolizing Inhaler Product Market
By Lauren Berg · April 29, 2024, 9:17 PM EDT
Boehringer Ingelheim Pharmaceuticals has manipulated the U.S. patent and drug approval system to unlawfully block makers of generic inhaler medications, health and welfare funds claimed in a lawsuit filed Monday in...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login